Small-Cap Firm Century Therapeutics' Expands into Autoimmune Diseases, Analyst Says Clade Therapeutics Acquisition IntriguingBenzinga • 24 days ago
Century Therapeutics unveils plans to expand CNTY-101 clinical development into additional autoimmune diseases, including systemic lupus erythematosus. $60 million private placement supports R&D...
Share to Feed
Medivir AB (publ) (OTCMKTS:MVRBF - Get Free Report) and Century Therapeutics (NASDAQ:IPSC - Get Free Report) are both medical companies, but which is the better business? We will contrast the two...
SAN MATEO, Calif., March 25, 2024 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Sagimet, Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel fatty acid synthase (FASN...
Shares of Century Therapeutics, Inc. (NASDAQ:IPSC Get Free Report) have been assigned a consensus rating of Moderate Buy from the six brokerages that are covering the company...
PHILADELPHIA, March 19, 2024 (GLOBE NEWSWIRE) -- Century Therapeutics (NASDAQ: IPSC), an innovative biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies in...
Century Therapeutics (NASDAQ:IPSC Free Report) had its price target upped by Canaccord Genuity Group from $22.00 to $24.00 in a research note issued to investors on Friday, Benzinga reports...
Century Therapeutics (NASDAQ:IPSC Get Free Report) had its price objective upped by analysts at Canaccord Genuity Group from $22.00 to $24.00 in a research report issued on Friday, Benzinga...
See the rest of the story here.
thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...
- Presented initial data from Phase 1 ELiPSE-1 Trial of CNTY-101 in relapsed/refractory B-cell lymphomas demonstrating a favorable tolerability profile, early clinical activity and indication that...
Innate Pharma (OTCMKTS:IPHYF Get Free Report) and Century Therapeutics (NASDAQ:IPSC Get Free Report) are both small-cap medical companies, but which is the better stock? We will...